Loading...
By Amy Orciari Herman
Edited by Susan Sadoughi, MD, and André Sofair, MD, MPH
Nearly 90 lots of losartan have been recalled because they contain higher-than-acceptable levels of N-nitroso-N-methyl-4-aminobutyric acid (NMBA), a potential human carcinogen, the FDA announced late last week. This is the third type of nitrosamine impurity leading to angiotensin-receptor-blocker (ARB) recalls since July 2018.
Like the other two impurities — N-nitrosodimethylamine (NDMA) and N-nitrosodiethylamine (NDEA) — NMBA appears to have been generated during the manufacturing process.
The FDA said the cancer risk posed by NDMA and NDEA in ARBs is "very low" — and the risk posed by NMBA "appears to be the same for NDMA exposure but less than the risk from NDEA exposure." The FDA is still evaluating these risks and "is committed to implementing measures to prevent the formation of these impurities ... in the future," agency commissioner Dr. Scott Gottlieb said.
In related news, on Friday 38 lots of valsartan-containing tablets were recalled owing to the presence of NDEA.
Comment
LINK(S):
FDA news release (Free)
Losartan recall notice (Free)
Valsartan recall notice (Free)
Background: Physician's First Watch coverage of valsartan shortage amid recalls (Free)